%0 Journal Article
%A Unglaub, Julia Marie
%A Schlenk, Richard
%A Middeke, Jan M
%A Krause, Stefan W
%A Kraus, Sabrina
%A Einsele, Hermann
%A Kramer, Michael
%A Zukunft, Sven
%A Kauer, Joseph
%A Renders, Simon
%A Katelari, Elena
%A Schliemann, Christoph
%A Pabst, Caroline
%A Luft, Thomas
%A Dreger, Peter
%A Röllig, Christoph
%A Bornhäuser, Martin
%A Müller-Tidow, Carsten
%A Sauer, Tim
%T Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML.
%J Blood advances
%V 9
%N 2
%@ 2473-9529
%C Washington, DC
%I American Society of Hematology
%M DKFZ-2024-01886
%P 375-385
%D 2025
%Z 2025 Jan 28;9(2):375-385
%X The BCL2-inhibitor Venetoclax (VEN) in combination with hypomethylating agents (HMA) has been approved for first-line treatment of acute myeloid leukemai (AML) patients ineligible for intensive treatment. Emerging Data suggest that VEN containing treatment strategies may also be effective in relapsed/refractory (R/R) AML, however, comparative studies with conventional treatment strategies for medically fit patients as a bridge-to transplant strategy are limited. Using propensity score matching (PSM) analysis, we compared 37 R/R AML patients, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic cell transplantation (allo-HCT) with 90 patients from the German Study Alliance Leukemia (SAL) AML registry, who were treated with non-VEN-containing salvage therapy according to their treating physician's choice (TPC) including intensive and non-intensive protocols. The overall response rate (ORR=CR+CRi) among all VEN patients was significantly higher compared to the TPC control cohort (62
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39293081
%R 10.1182/bloodadvances.2024013086
%U https://inrepo02.dkfz.de/record/293338